#Canada #Ontario #HemoScreen #PixCell Medical #Inter Medico

PixCell Medical Expands into Canada

PixCell Medical, a pioneering company focused on innovative hematology solutions, has made significant strides into the Canadian market through a strategic partnership with Inter Medico. This expansion comes on the heels of receiving authorization from Health Canada for its groundbreaking HemoScreen™ device, a point-of-care hematology analyzer designed to deliver high-quality Complete Blood Count (CBC) testing rapidly and efficiently.

The HemoScreen Advantage

Situated as a crucial advancement in decentralized diagnostics, HemoScreen requires only a drop of venous or capillary blood to conduct its tests. The device is distinguished by its combination of AI-powered digital imaging and proprietary Viscoelastic Focusing technology, all incorporated within a fully self-contained disposable cartridge. This innovative design eliminates the need for maintenance, calibration, external reagents, or liquid waste, offering lab-quality testing capabilities in settings where standard laboratory analyzers may be impractical, such as in rural community clinics and hospitals.

Addressing Canada’s Unique Healthcare Challenges

Canada is the second-largest country in the world by land area, presenting unique challenges for healthcare delivery, particularly in terms of timely diagnostic services. With nearly 20% of the Canadian population residing in rural areas, access to rapid and effective diagnostic testing becomes even more critical. PixCell Medical’s expansion and the introduction of HemoScreen are timely responses to this growing demand for decentralized diagnostics. The system allows healthcare providers to perform CBC testing closer to patients, contributing to more immediate clinical decision-making and potentially improving health outcomes.

A Strategic Partnership with Inter Medico

Inter Medico brings over 45 years of experience in providing cutting-edge diagnostic technologies across Canada. Their established presence and expertise in the healthcare market are invaluable assets that will help facilitate the introduction of HemoScreen to Canadian clinicians and patients. According to Dan Lichtman, CEO of Inter Medico, the partnership aims to ensure that all healthcare providers, especially those in small, remote communities, have access to this innovative technology that has already demonstrated its effectiveness in various other countries.

Future Implications for Patient Care

Dr. Avishay Bransky, CEO and co-founder of PixCell Medical, emphasizes the significance of the Health Canada authorization as a pivotal moment for expanding access to rapid hematology testing worldwide. With the support of Inter Medico, PixCell Medical aims to make lab-quality CBC testing available in various healthcare settings across Canada, thereby paving the way for timely interventions that can significantly enhance patient care.

About PixCell Medical

Founded with the mission to revolutionize hematology testing, PixCell Medical has developed the HemoScreen as its flagship product. This device has gained recognition as the first FDA-cleared 5-part differential CBC analyzer tailored for point-of-care environments, making it a vital tool for hospitals, clinics, and decentralized healthcare facilities around the globe.

About Inter Medico

Inter Medico specializes in offering leading-edge instrumentation and reagent solutions tailored to the Canadian healthcare market. Their commitment to quality service and support over the past four decades has positioned them as a trusted partner for healthcare providers across the nation.

Conclusion

With the launch of HemoScreen in Canada, PixCell Medical and Inter Medico are poised to reshape the landscape of diagnostic services, bringing technology directly to the patients who need it most and ensuring comprehensive care remains at the forefront of Canadian healthcare initiatives.